Tigapotide Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414800

CAS#: 848084-83-3 (free base)

Description: Tigapotide Free Base is a synthetic peptide corresponding to amino acids 31-45 of PSP94 (prostate secretory protein) that inhibits matrix metalloproteinase-9 secretion.

Chemical Structure

img
Tigapotide Free Base
CAS# 848084-83-3 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 414800
Name: Tigapotide Free Base
CAS#: 848084-83-3 (free base)
Chemical Formula: C82H119N21O34S3
Exact Mass: 2,037.74
Molecular Weight: 2,039.150
Elemental Analysis: C, 48.30; H, 5.88; N, 14.43; O, 26.68; S, 4.72

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 848084-84-4 (triflutate); 848084-83-3 (free base)  

Synonym: Tigapotide Free Base; PCK-3145; PCK3145; PCK 3145

IUPAC/Chemical Name: (2S,5S,8S,11R,14S,17R,20S,23S,26R,29S,32S,35S,38S,41S,44S)-41-((1H-indol-3-yl)methyl)-11,17,26-tris(((acetamidomethyl)thio)methyl)-44-amino-29-(2-amino-2-oxoethyl)-38-(3-amino-3-oxopropyl)-5,23-bis(2-carboxyethyl)-32-(carboxymethyl)-8-(4-hydroxybenzyl)-2,14,20,35-tetrakis((R)-1-hydroxyethyl)-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecaoxo-3,6,9,12,15,18,21,24,27,30,33,36,39,42-tetradecaazaheptatetracontanedioic acid

InChi Key: ZRXXHPDJLAQCPC-SFJRRRFZSA-N

InChi Code: InChI=1S/C82H119N21O34S3/c1-35(104)64(100-69(123)48(17-20-58(84)112)90-73(127)52(93-68(122)46(83)16-21-60(114)115)25-43-28-86-47-11-9-8-10-45(43)47)79(133)96-54(27-63(120)121)75(129)95-53(26-59(85)113)74(128)97-55(29-138-32-87-39(5)108)76(130)92-49(18-22-61(116)117)70(124)101-65(36(2)105)80(134)99-57(31-140-34-89-41(7)110)78(132)102-66(37(3)106)81(135)98-56(30-139-33-88-40(6)109)77(131)94-51(24-42-12-14-44(111)15-13-42)72(126)91-50(19-23-62(118)119)71(125)103-67(38(4)107)82(136)137/h8-15,28,35-38,46,48-57,64-67,86,104-107,111H,16-27,29-34,83H2,1-7H3,(H2,84,112)(H2,85,113)(H,87,108)(H,88,109)(H,89,110)(H,90,127)(H,91,126)(H,92,130)(H,93,122)(H,94,131)(H,95,129)(H,96,133)(H,97,128)(H,98,135)(H,99,134)(H,100,123)(H,101,124)(H,102,132)(H,103,125)(H,114,115)(H,116,117)(H,118,119)(H,120,121)(H,136,137)/t35-,36-,37-,38-,46+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,64+,65+,66+,67+/m1/s1

SMILES Code: C[C@H]([C@@H](C(O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@H](CCC(O)=O)N)=O)Cc(c[nH]1)c2c1cccc2)=O)CCC(N)=O)=O)=O)CC(O)=O)=O)CC(N)=O)=O)CSCNC(C)=O)=O)CCC(O)=O)=O)=O)CSCNC(C)=O)=O)=O)CSCNC(C)=O)=O)Cc3ccc(O)cc3)=O)CCC(O)=O)=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 2,039.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Shukeir N, Garde S, Wu JJ, Panchal C, Rabbani SA. Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anticancer Drugs. 2005 Nov;16(10):1045-51. doi: 10.1097/00001813-200511000-00002. PMID: 16222145.

2: Danika C, El Mubarak MA, Leontari I, Sivolapenko GB. Development and validation of analytical methodologies for the quantification of PCK3145 and PEG-PCK3145 in mice. Anal Biochem. 2019 Jan 1;564-565:72-79. doi: 10.1016/j.ab.2018.10.005. Epub 2018 Oct 17. PMID: 30339813.

3: Kostopoulos A, Papageorgiou E, Koutsilieris M, Sivolapenko G. PCK3145 inhibits proliferation and induces apoptosis in breast and colon cancer cells. Anticancer Res. 2015 Mar;35(3):1377-84. PMID: 25750288.

4: Yan BX, Ma JX, Zhang J, Guo Y, Riedel H, Mueller MD, Remick SC, Yu JJ. PSP94 contributes to chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer. Oncogene. 2014 Nov 6;33(45):5288-94. doi: 10.1038/onc.2013.466. Epub 2013 Nov 4. PMID: 24186202.

5: El Mubarak MA, Leontari I, Danika C, Katsila T, Sivolapenko G. Development and validation of a UHPLC-UV method for the determination of a prostate secretory protein 94-derived synthetic peptide (PCK3145) in human plasma and assessment of its stability in human plasma. Biomed Chromatogr. 2016 Sep;30(9):1476-80. doi: 10.1002/bmc.3708. Epub 2016 Mar 21. PMID: 26892539.

6: Annabi B, Currie JC, Bouzeghrane M, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding. Biochem Biophys Res Commun. 2006 Jul 21;346(1):358-66. doi: 10.1016/j.bbrc.2006.05.139. Epub 2006 Jun 2. PMID: 16759641.

7: Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis. Clin Exp Metastasis. 2005;22(5):429-39. doi: 10.1007/s10585-005-2669-1. PMID: 16283486.

8: Annabi B, Bouzeghrane M, Currie JC, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. Inhibition of MMP-9 secretion by the anti- metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anticancer Drugs. 2006 Apr;17(4):429-38. doi: 10.1097/01.cad.0000203388.68034.06. PMID: 16550001.

9: Lamy S, Ruiz MT, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Annabi B. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis. Int J Cancer. 2006 May 1;118(9):2350-8. doi: 10.1002/ijc.21615. PMID: 16331603.

10: Hawkins RE, Daigneault L, Cowan R, Griffiths R, Panchal C, Armstrong A, Fenemore J, Irvine A, Sereda K, Dulude H. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clin Prostate Cancer. 2005 Sep;4(2):91-9. doi: 10.3816/cgc.2005.n.016. PMID: 16197609.